Zacks Investment Research on MSN
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from ...
U.S.-based Tempus AI (TEM) stock is up in early trading on Monday. Yesterday, the company received FDA clearance for its RNA-based Tempus xR IVD device. Following the news, TEM stock hit an all-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results